<p>Brummer Multi Strategy AB 在最近向證券交易委員會提交的文件中表示，在第四季度購買了 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - 免費報告) 的新頭寸。這家機構投資者購買了 457,707 股該公司的股票，價值約為 1,488,000 美元。Maravai LifeSciences 約佔 Brummer Multi Strategy AB 投資組合的 9.0%，使其成為第六大持倉。截至最近向證券交易委員會提交的文件，Brummer Multi Strategy AB 擁有 Maravai LifeSciences 約 0.18% 的股份。</p>
<p>獲取 <strong>Maravai LifeSciences</strong> 的提醒：</p>
<p>其他機構投資者和對沖基金也買賣了該公司的股票。Tejara Capital Ltd 在第三季度將其在 Maravai LifeSciences 的持股增加了 26.4%。Tejara Capital Ltd 現在擁有 2,453,441 股該公司的股票，價值 7,041,000 美元，此前在上個季度又收購了 511,992 股。Monaco Asset Management SAM 在第三季度將其在 Maravai LifeSciences 的持股增加了 315.0%。Monaco Asset Management SAM 現在擁有 3,656,337 股該公司的股票，價值 10,494,000 美元，此前在上個季度又收購了 2,775,372 股。First Eagle Investment Management LLC 在第三季度收購了 Maravai LifeSciences 的新頭寸，價值約為 1,294,000 美元。Royce &amp; Associates LP 在第三季度將其在 Maravai LifeSciences 的持倉增加了 38.0%。Royce &amp; Associates LP 現在擁有 1,761,764 股該公司的股票，價值 5,056,000 美元，此前在上個季度又購買了 484,908 股。最後，General American Investors Co. Inc. 在第三季度收購了 Maravai LifeSciences 的新頭寸，價值約為 391,000 美元。機構投資者擁有該公司 50.25% 的股份。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些股票分析師對 MRVI 股票發表了看法。德意志銀行重申了對 Maravai LifeSciences 的 “買入” 評級，並在週五的研究報告中設定了 6.00 美元的目標價。富國銀行將 Maravai LifeSciences 的目標價從 4.50 美元上調至 5.50 美元，並在週五的研究報告中給予該股票 “超配” 評級。最後，Wall Street Zen 在 2 月 28 日的研究報告中將 Maravai LifeSciences 的評級從 “賣出” 上調至 “持有”。四位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，共識目標價為 5.70 美元。</p>
<p><strong>查看我們對 Maravai LifeSciences 的最新分析</strong></p>
<h2>Maravai LifeSciences 股票表現</h2>
<p>NASDAQ:MRVI 的股票週一開盤價為 4.85 美元。該公司的市值為 12.5 億美元，市盈率為 -6.83，貝塔值為 0.62。Maravai LifeSciences Holdings, Inc. 的一年最低價為 1.95 美元，一年最高價為 4.95 美元。該公司的債務與股本比率為 0.85，流動比率為 6.60，速動比率為 5.69。該業務的 50 日簡單移動平均線為 3.33 美元，200 日簡單移動平均線為 3.39 美元。</p>
<p>Maravai LifeSciences (NASDAQ:MRVI - 獲取免費報告) 最近在 5 月 7 日發佈了季度財報。該公司報告每股收益 (EPS) 為 0.01 美元，超出分析師的共識預期（-0.05 美元）0.06 美元。該業務在本季度的收入為 6,584 萬美元，而共識預期為 5,300 萬美元。Maravai LifeSciences 的股本回報率為 -17.29%，淨利潤率為 -51.07%。研究分析師預計，Maravai LifeSciences Holdings, Inc. 在當前財政年度將發佈 -0.26 的每股收益。</p>
<h2>關於 Maravai LifeSciences</h2>
<p>(免費報告)</p>
<p>Maravai LifeSciences Holdings, Inc NASDAQ: MRVI 是一家生命科學公司，專注於開發和提供生物治療開發和生產所需的關鍵試劑和服務。該公司的產品支持基因組學、分子診斷、疫苗開發和下一代測序等多種應用。Maravai 的平台解決了生物製藥行業中核酸生產、蛋白質檢測、表觀遺傳分析和試劑質量等關鍵挑戰。</p>
<p>通過其產品組合，包括專有的 mRNA 封閉試劑、脂質納米顆粒遞送系統、合成寡核苷酸和高精度檢測工具，Maravai 使客户能夠加速研究並簡化製造工作流程。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Maravai LifeSciences</li>
<li>超越 NVIDIA：強勁勢頭的 AI 相關股票推薦</li>
<li>量子財報季正在升温——關注兩大主要參與者的動態</li>
<li>Flutter 在財報後看到提升，FanDuel 顯示覆蘇跡象</li>
<li>3 只醫療保健股票將從一項重大法案中受益</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJWSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJWSQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Maravai LifeSciences 嗎？</h2>
<p>在你考慮 Maravai LifeSciences 之前，你會想聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Maravai LifeSciences 並不在名單上。</p>
<p>雖然 Maravai LifeSciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看五隻股票</p>

MRVI

動態生物技術與基因組 ETF - Invesco

IBBQ

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做多 - Direxion

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 ETF - SPDR

<p>Brummer Multi Strategy AB 在第四季度收購了 457,707 股 Maravai LifeSciences Holdings, Inc.（納斯達克代碼：MRVI），價值約為 149 萬美元，使其成為其投資組合中第六大持倉。其他機構投資者也增加了對 Maravai 的持股。分析師對 MRVI 的一致評級為 “適度買入”，目標價為 5.70 美元。Maravai 報告的季度每股收益為 0.01 美元，超出預期，收入為 6584 萬美元。該股票開盤價為 4.85 美元，市值為 12.5 億美元</p>

<p>Brummer Multi Strategy AB bought a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor bought 457,707 shares of the company's stock, valued at approximately $1,488,000. Maravai LifeSciences makes up approximately 9.0% of Brummer Multi Strategy AB's portfolio, making the stock its 6th largest position. Brummer Multi Strategy AB owned about 0.18% of Maravai LifeSciences as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>Brummer Multi Strategy AB 在最近向證券交易委員會提交的文件中表示，在第四季度購買了 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - 免費報告) 的新頭寸。這家機構投資者購買了 457,707 股該公司的股票，價值約為 1,488,000 美元。Maravai LifeSciences 約佔 Brummer Multi Strategy AB 投資組合的 9.0%，使其成為第六大持倉。截至最近向證券交易委員會提交的文件，Brummer Multi Strategy AB 擁有 Maravai LifeSciences 約 0.18% 的股份。</p>
</div><p>Get <strong>Maravai LifeSciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Maravai LifeSciences</strong> 的提醒：</p>
</div><p>Other institutional investors and hedge funds have also bought and sold shares of the company. Tejara Capital Ltd raised its holdings in Maravai LifeSciences by 26.4% during the third quarter. Tejara Capital Ltd now owns 2,453,441 shares of the company's stock worth $7,041,000 after acquiring an additional 511,992 shares in the last quarter. Monaco Asset Management SAM raised its holdings in Maravai LifeSciences by 315.0% during the third quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company's stock worth $10,494,000 after acquiring an additional 2,775,372 shares in the last quarter. First Eagle Investment Management LLC acquired a new position in Maravai LifeSciences during the third quarter worth approximately $1,294,000. Royce &amp; Associates LP increased its position in Maravai LifeSciences by 38.0% during the third quarter. Royce &amp; Associates LP now owns 1,761,764 shares of the company's stock worth $5,056,000 after buying an additional 484,908 shares during the last quarter. Finally, General American Investors Co. Inc. acquired a new position in Maravai LifeSciences during the third quarter worth approximately $391,000. Institutional investors own 50.25% of the company's stock.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金也買賣了該公司的股票。Tejara Capital Ltd 在第三季度將其在 Maravai LifeSciences 的持股增加了 26.4%。Tejara Capital Ltd 現在擁有 2,453,441 股該公司的股票，價值 7,041,000 美元，此前在上個季度又收購了 511,992 股。Monaco Asset Management SAM 在第三季度將其在 Maravai LifeSciences 的持股增加了 315.0%。Monaco Asset Management SAM 現在擁有 3,656,337 股該公司的股票，價值 10,494,000 美元，此前在上個季度又收購了 2,775,372 股。First Eagle Investment Management LLC 在第三季度收購了 Maravai LifeSciences 的新頭寸，價值約為 1,294,000 美元。Royce &amp; Associates LP 在第三季度將其在 Maravai LifeSciences 的持倉增加了 38.0%。Royce &amp; Associates LP 現在擁有 1,761,764 股該公司的股票，價值 5,056,000 美元，此前在上個季度又購買了 484,908 股。最後，General American Investors Co. Inc. 在第三季度收購了 Maravai LifeSciences 的新頭寸，價值約為 391,000 美元。機構投資者擁有該公司 50.25% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of equities analysts have weighed in on MRVI shares. Deutsche Bank Aktiengesellschaft reissued a &#34;buy&#34; rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday. Wells Fargo &amp; Company boosted their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the stock an &#34;overweight&#34; rating in a research report on Friday. Finally, Wall Street Zen raised Maravai LifeSciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, February 28th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $5.70.</p>
<div class="lb-trans"><p>一些股票分析師對 MRVI 股票發表了看法。德意志銀行重申了對 Maravai LifeSciences 的 “買入” 評級，並在週五的研究報告中設定了 6.00 美元的目標價。富國銀行將 Maravai LifeSciences 的目標價從 4.50 美元上調至 5.50 美元，並在週五的研究報告中給予該股票 “超配” 評級。最後，Wall Street Zen 在 2 月 28 日的研究報告中將 Maravai LifeSciences 的評級從 “賣出” 上調至 “持有”。四位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “適度買入”，共識目標價為 5.70 美元。</p>
</div><p><strong>View Our Latest Analysis on Maravai LifeSciences</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Maravai LifeSciences 的最新分析</strong></p>
</div><h2>Maravai LifeSciences Stock Performance</h2>
<div class="lb-trans"><h2>Maravai LifeSciences 股票表現</h2>
</div><p>Shares of NASDAQ:MRVI opened at $4.85 on Monday. The company has a market capitalization of $1.25 billion, a P/E ratio of -6.83 and a beta of 0.62. Maravai LifeSciences Holdings, Inc. has a 1 year low of $1.95 and a 1 year high of $4.95. The company has a debt-to-equity ratio of 0.85, a current ratio of 6.60 and a quick ratio of 5.69. The business's 50 day simple moving average is $3.33 and its 200 day simple moving average is $3.39.</p>
<div class="lb-trans"><p>NASDAQ:MRVI 的股票週一開盤價為 4.85 美元。該公司的市值為 12.5 億美元，市盈率為 -6.83，貝塔值為 0.62。Maravai LifeSciences Holdings, Inc. 的一年最低價為 1.95 美元，一年最高價為 4.95 美元。該公司的債務與股本比率為 0.85，流動比率為 6.60，速動比率為 5.69。該業務的 50 日簡單移動平均線為 3.33 美元，200 日簡單移動平均線為 3.39 美元。</p>
</div><p>Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.06. The business had revenue of $65.84 million for the quarter, compared to the consensus estimate of $53.00 million. Maravai LifeSciences had a negative return on equity of 17.29% and a negative net margin of 51.07%. On average, research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.26 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Maravai LifeSciences (NASDAQ:MRVI - 獲取免費報告) 最近在 5 月 7 日發佈了季度財報。該公司報告每股收益 (EPS) 為 0.01 美元，超出分析師的共識預期（-0.05 美元）0.06 美元。該業務在本季度的收入為 6,584 萬美元，而共識預期為 5,300 萬美元。Maravai LifeSciences 的股本回報率為 -17.29%，淨利潤率為 -51.07%。研究分析師預計，Maravai LifeSciences Holdings, Inc. 在當前財政年度將發佈 -0.26 的每股收益。</p>
</div><h2>About Maravai LifeSciences</h2>
<div class="lb-trans"><h2>關於 Maravai LifeSciences</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.</p>
<div class="lb-trans"><p>Maravai LifeSciences Holdings, Inc NASDAQ: MRVI 是一家生命科學公司，專注於開發和提供生物治療開發和生產所需的關鍵試劑和服務。該公司的產品支持基因組學、分子診斷、疫苗開發和下一代測序等多種應用。Maravai 的平台解決了生物製藥行業中核酸生產、蛋白質檢測、表觀遺傳分析和試劑質量等關鍵挑戰。</p>
</div><p>Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.</p>
<div class="lb-trans"><p>通過其產品組合，包括專有的 mRNA 封閉試劑、脂質納米顆粒遞送系統、合成寡核苷酸和高精度檢測工具，Maravai 使客户能夠加速研究並簡化製造工作流程。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Maravai LifeSciences</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Maravai LifeSciences</li>
<li>超越 NVIDIA：強勁勢頭的 AI 相關股票推薦</li>
<li>量子財報季正在升温——關注兩大主要參與者的動態</li>
<li>Flutter 在財報後看到提升，FanDuel 顯示覆蘇跡象</li>
<li>3 只醫療保健股票將從一項重大法案中受益</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJWSQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MRVI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Maravai LifeSciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Maravai LifeSciences 嗎？</h2>
</div><p>Before you consider Maravai LifeSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Maravai LifeSciences 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Maravai LifeSciences 並不在名單上。</p>
</div><p>While Maravai LifeSciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Maravai LifeSciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看五隻股票</p>
</div>

457,707 Shares in Maravai LifeSciences Holdings, Inc. $MRVI Purchased by Brummer Multi Strategy AB

Market Beat

Maravai LifeSciences

Invesco Nasdaq Biotechnology ETF

德意志銀行

富國銀行

英偉達

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

NVIDIA Corporation

Brummer Multi Strategy AB 購入了 457,707 股 Maravai LifeSciences Holdings, Inc.（股票代碼：$MRVI）的股票